Back to top
more

Eisai Co. (ESALY)

(Delayed Data from OTC)

$58.36 USD

58.36
3,991

+0.51 (0.89%)

Updated May 3, 2019 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

UTHR or ESALY: Which Is the Better Value Stock Right Now?

UTHR vs. ESALY: Which Stock Is the Better Value Option?

UTHR vs. ESALY: Which Stock Is the Better Value Option?

UTHR vs. ESALY: Which Stock Is the Better Value Option?

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

UTHR vs. ESALY: Which Stock Is the Better Value Option?

UTHR vs. ESALY: Which Stock Is the Better Value Option?

New Strong Sell Stocks for September 30th

CGC, ESALY and META have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2022.

New Strong Sell Stocks for June 8th

APAM, CNVY, and ESALY have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2022.

Best Income Stocks to Buy for March 1st

GOGL, ESALY, and ADM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2022

Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study

Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

New Strong Sell Stocks for July 6th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Xencor (XNCR) Jumps: Stock Rises 7.4%

Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear

The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear

John Blank headshot

The G20 Meeting Cometh: Global Week Ahead

The weekend's G20 meeting in Osaka, Japan -- starting on Friday and running into Saturday -- should be the week's main event. But it is a closer.

Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

Catalent Acquires Gene Therapy Leader Paragon Bioservices

Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher

CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

Why Eisai (ESALY) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Eisai (ESALY).